Clearpoint Total Current Liabilities from 2010 to 2025
| CLPT Stock | USD 12.42 0.04 0.32% |
Total Current Liabilities | First Reported 2011-12-31 | Previous Quarter 7.6 M | Current Value 10.4 M | Quarterly Volatility 3.1 M |
Check Clearpoint Neuro financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Clearpoint Neuro's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 330 K or Selling General Administrative of 7.9 M, as well as many indicators such as Price To Sales Ratio of 7.36, Dividend Yield of 0.0 or PTB Ratio of 17.19. Clearpoint financial statements analysis is a perfect complement when working with Clearpoint Neuro Valuation or Volatility modules.
Clearpoint | Total Current Liabilities |
Latest Clearpoint Neuro's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Clearpoint Neuro over the last few years. Total Current Liabilities is an item on Clearpoint Neuro balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Clearpoint Neuro are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Clearpoint Neuro's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Clearpoint Neuro's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Clearpoint Total Current Liabilities Regression Statistics
| Arithmetic Mean | 7,056,556 | |
| Geometric Mean | 6,043,663 | |
| Coefficient Of Variation | 56.62 | |
| Mean Deviation | 3,272,437 | |
| Median | 6,788,000 | |
| Standard Deviation | 3,995,336 | |
| Sample Variance | 16T | |
| Range | 12.6M | |
| R-Value | (0.22) | |
| Mean Square Error | 16.3T | |
| R-Squared | 0.05 | |
| Significance | 0.41 | |
| Slope | (187,385) | |
| Total Sum of Squares | 239.4T |
Clearpoint Total Current Liabilities History
About Clearpoint Neuro Financial Statements
Clearpoint Neuro shareholders use historical fundamental indicators, such as Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Clearpoint Neuro investors may analyze each financial statement separately, they are all interrelated. The changes in Clearpoint Neuro's assets and liabilities, for example, are also reflected in the revenues and expenses on on Clearpoint Neuro's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 10.4 M | 10.9 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.